Case-based MCQ
Enhance Your Medical Expertise with Case Based MCQ – Your Go-To Telegram Channel for Challenging, Real-World MCQs and Continuous Learning. Admin: @Mohamm_ADs
Show more📈 Analytical overview of Telegram channel Case-based MCQ
Channel Case-based MCQ (@casebasedmcq) in the English language segment is an active participant. Currently, the community unites 19 232 subscribers, ranking 1 205 in the Medicine category and 22 628 in the India region.
📊 Audience metrics and dynamics
Since its creation on невідомо, the project has demonstrated rapid growth, gathering an audience of 19 232 subscribers.
According to the latest data from 20 June, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by -190 over the last 30 days and by -9 over the last 24 hours, overall reach remains high.
- Verification status: Not verified
- Engagement rate (ER): The average audience engagement rate is 2.22%. Within the first 24 hours after publication, content typically collects 0.71% reactions from the total number of subscribers.
- Post reach: On average, each post receives 427 views. Within the first day, a publication typically gains 137 views.
- Reactions and interaction: The audience actively supports content: the average number of reactions per post is 1.
- Thematic interests: Content is focused on key topics such as boardvital, bmj, journal, usmle, drug.
📝 Description and content policy
The author describes the resource as a platform for expressing subjective opinions:
“Enhance Your Medical Expertise with Case Based MCQ – Your Go-To Telegram Channel for Challenging, Real-World MCQs and Continuous Learning.
Admin: @Mohamm_ADs”
Thanks to the high frequency of updates (latest data received on 21 June, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.
3%-16% of pregnancies. It is thought to be a variation of Hashimoto’s disease and can present in several ways. It can cause hyperthyroidism, beginning 1-4 months after delivery and lasting for 2-8 weeks. Thyroid function then either returns to normal or the patient develops transient or permanent hypothyroidism. Another possible manifestation is hypothyroidism beginning 2-6 months after delivery, which again can either be transient or become permanent. A third possibility is that the patient can develop a euthyroid goiter. As in this case, the symptoms are usually mild, and can be confused with the typical feelings of a new mother. Since the symptoms are mild and the hyperthyroid stage is brief, treatment is not necessary in the majority of cases. The hyperthyroid symptoms should be explained to the patient, and she should also be made aware of the symptoms of
hypothyroidism, since it is a common development after the hyperthyroid stage has passed and may be permanent. Breastfeeding was going well in this patient, and should be continued. Propranolol is not needed unless the palpitations worsen. Propylthiouracil is used for Graves’ disease, to counteract overproduction of thyroid hormone. With postpartum thyroiditis, as with other types of thyroiditis, thyroid hormone is released from the gland as a result of autoimmune injury, but production of thyroid hormone is actually low. Propylthiouracil has no place in the treatment of thyroiditis. Radioactive thyroid scanning is not necessary unless symptoms are significant and are not resolving, in which case
Graves’ disease masquerading as thyroiditis must be ruled out. Thyroiditis would cause low uptake, but this has no
bearing as to whether thyroid hormone needs to be given. Thyroid hormone is used in postpartum thyroiditis if the person is found to be hypothyroid (with high levels of TSH), with symptoms significant enough to require treatment. Treatment would be continued for 1-2 months and then stopped, and the TSH level rechecked 1 month later to see if the hypothyroid condition has resolved
Available now! Telegram Research 2025 — the year's key insights 
